HemoScreen SIGNED
Point-of-care hematology analyser based on visco-elastic focusing, digital imaging, image processing and machine learning
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0HemoScreen project word cloud
Explore the words cloud of the HemoScreen project. It provides you a very rough idea of what is the project "HemoScreen" about.
Project "HemoScreen" data sheet
The following table provides information about the project.
| Coordinator |
PIXCELL MEDICAL TECHNOLOGIES LTD
Organization address contact info |
| Coordinator Country | Israel [IL] |
| Total cost | 3˙556˙337 € |
| EC max contribution | 2˙489˙436 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-06-01 to 2020-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | PIXCELL MEDICAL TECHNOLOGIES LTD | IL (YOKNEAM ILIT) | coordinator | 2˙489˙436.00 |
Map
Project objective
HemoScreen is the first true point-of-care hematology analyser: a portable (8kg) and affordable (€4,500) device that can be operated by any medical personnel (no maintenance or calibration). The analyser uses low-cost (€8) disposable cartridges containing a high performance microfluidic chip. The phase 1 market study identified three priority segments for market introduction: physician office labs (POL), oncology and neonatal. In all 3 segments, HemoScreen can reduce the cost of the blood test by at least 50% as physicians can run the test with their own equipment instead of purchasing it from an external lab. More importantly, physicians can get immediate (9 min) results instead of waiting for 24-72 hours, cutting operational inefficiencies, reducing medical transcription errors, improving patient safety, minimizing the time to adequate treatment and ultimately, improving patient outcomes. HemoScreen relies on direct cell characterization based on imaging, the gold standard for cell classification, and a patented visco-elastic focusing method, which is more robust and efficient than hydrodynamic focusing (used in flow cytometry). The technology has already generated 7 patent families and 3 more are expected to be filed during this project. The project will conduct a series of trials involving over 4,000 blood tests over 5 trial sites spread between Sweden, Belgium, UK and USA. The trial results will be used for product improvement, industrialization and certification. Based on preliminary feedback from the FDA, the HemoScreen is the first true hematology POC analyser designed in accordance with CLIA waiver requirements, enabling thousands of physicians to run their own blood tests without requiring any lab certification. PixCell’s vision is to make cell-based diagnostics as simple as a glucose test and revolutionize POC diagnostics. Following a full market launch in 2020, PixCell medical forecasts revenues of €36M and headcount of 85 employees by 2022.
Deliverables
| Project website | Websites, patent fillings, videos etc. | 2020-01-16 15:53:22 |
Take a look to the deliverables list in detail: detailed list of HemoScreen deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Anders Larsson Hämatologi, ett laboratorieområde som kanske står inför stora förändringar published pages: , ISSN: 1101-2013, DOI: |
Nordisk Forening for Klinisk Kemi | 2020-01-16 |
| 2019 |
Anders Larsson, Lena Carlsson, Bo Karlsson, Miklos Lipcsey Rapid testing of red blood cell parameters in primary care patients using HemoScreenâ„¢ point of care instrument published pages: , ISSN: 1471-2296, DOI: 10.1186/s12875-019-0971-2 |
BMC Family Practice 20/1 | 2020-01-16 |
| 2018 |
Anders Larsson, David Smekal, Miklos Lipcsey Rapid testing of red blood cells, white blood cells and platelets in intensive care patients using the HemoScreenâ„¢ point-of-care analyzer published pages: 1-4, ISSN: 0953-7104, DOI: 10.1080/09537104.2018.1557619 |
Platelets | 2020-01-16 |
| 2018 |
Miklos Lipcsey, Johanna Helmersson-Karlqvist, Anders Larsson Point of Care Testing of Red Blood Cells and Platelets in Intensive Care Patients Using HemoScreen published pages: , ISSN: , DOI: |
2020-01-16 | |
| 2018 |
Miklos Lipcsey, Johanna Helmersson-Karlqvist, Anders Larsson Rapid testing of red blood cells and platelets in intensive care patients using HemoScreenâ„¢ point of care instrument published pages: , ISSN: , DOI: |
2020-01-16 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEMOSCREEN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HEMOSCREEN" are provided by the European Opendata Portal: CORDIS opendata.
